Understanding The Potential of LLRTM1 as A Drug Target Or Biomarker

Target Name: LRRTM1

NCBI ID: G347730

LRRTM1

Understanding The Potential of LLRTM1 as A Drug Target Or Biomarker

LRRTM1 (LRRT1_HUMAN), also known as human long short-chain RhoA-associated protein 1, is a protein that is expressed in various tissues throughout the body, including muscle, nerve, and heart. It is a member of the RhoA gene family, which is known for its role in cell signaling and cytoskeletal organization.

LRRT1 has been identified as a potential drug target or biomarker due to its unique structure and the diseases it is associated with. One of the key features of LRRTM1 is its ability to interact with various signaling pathways, including the RhoA pathway. This interaction has led to the hypothesis that LRRTM1 could be a drug target for diseases that are characterized by the over-expression or dysfunction of RhoA signaling pathways.

In addition to its potential as a drug target, LLRTM1 has also been identified as a biomarker for several diseases. For example, LRRTM1 has been shown to be upregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This upregulation has been associated with the development or progression of these diseases, which suggests that LLRTM1 may be a valuable biomarker for these conditions.

The structure of LRRTM1 has also been the subject of investigation, as its unique shape and interactions with other proteins have led to the hypothesis that it may play a unique role in cell signaling. LRRTM1 is a 21-kDa protein that contains 11 unique domains, including a long N-terminus that is involved in protein-protein interactions and a C-terminus that is involved in cell signaling.

One of the most interesting features of LRRTM1 is its ability to form a complex with the protein GFR伪1, which is a key regulator of the RhoA pathway. This complex has been shown to play a role in the regulation of cellular processes such as cell growth, differentiation, and survival.

In addition to its potential as a drug target and biomarker, LLRTM1 is also of interest to researchers due to its unique structure and the diseases it is associated with. Studies are being conducted to further understand the role of LRRTM1 in disease, as well as to explore its potential as a drug or biomarker.

Overall, LLRTM1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its unique structure and interactions with other proteins make it an attractive candidate for further investigation and study. Further research is needed to fully understand the role of LLRTM1 in disease and to explore its potential as a drug or biomarker.

Protein Name: Leucine Rich Repeat Transmembrane Neuronal 1

Functions: Exhibits strong synaptogenic activity, restricted to excitatory presynaptic differentiation, acting at both pre- and postsynaptic level

The "LRRTM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRTM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets